Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03978520 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 341
- Enrollment target
NCT03978520 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 341 participants.
The verdict
NCT03978520, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 341 participants
- Enrollment target
Study Summary
The main objective of this study was to evaluate the safety and efficacy of elsubrutinib, upadacitinib (UPA), and ABBV-599 (elsubrutinib/upadacitinib) High Dose and Low Dose combinations vs placebo for the treatment of signs and symptoms of Systemic Lupus Erythematosus (SLE) in participants with moderately to severely active SLE and to define doses for further development.
Interventions
- DRUG Upadacitinib
- DRUG Placebo for upadacitinib
- DRUG Elsubrutinib
- DRUG Placebo for elsubrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2022-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03978520
The ClinicalTrials.gov registry entry for NCT03978520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Upadacitinib is the first listed.
NCT03978520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03978520 about?
NCT03978520 is a clinical study titled "A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)". The main objective of this study was to evaluate the safety and efficacy of elsubrutinib, upadacitinib (UPA), and ABBV-599 (elsubrutinib/upadacitinib) High Dose and Low Dose combinations vs placebo for the treatment of signs and symptoms of Systemic Lupus Erythematosus (SLE) in participants with mod...
What is the current status of trial NCT03978520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 341 participants. The study started on 2019-07-25. Estimated completion is 2022-07-14.
What interventions are being tested in trial NCT03978520?
The interventions under investigation include: Upadacitinib (DRUG), Placebo for upadacitinib (DRUG), Elsubrutinib (DRUG), Placebo for elsubrutinib (DRUG).
Who is sponsoring clinical trial NCT03978520?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.